Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 3.42M | 181.80K | 305.70K | 515.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 3.42M | 181.80K | 305.70K | 515.00K |
| Cost of Revenue | 3.80M | 1.69M | 947.20K | 778.90K | 2.23M |
| Gross Profit | -2.50M | 1.73M | -765.40K | -473.20K | -1.72M |
| SG&A Expenses | 1.08M | 1.08M | 1.19M | 1.37M | 1.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.88M | 2.77M | 2.14M | 2.15M | 3.67M |
| Operating Income | -3.58M | 644.70K | -1.96M | -1.84M | -3.16M |
| Income Before Tax | -3.56M | 661.80K | -1.97M | -3.12M | -3.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.56M | 661.80K | -1.97M | -3.12M | -3.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -- | -- | 100.00 | 1.00K |
| Net Income | -3.56M | 661.80K | -1.97M | -3.12M | -3.50M |
| EBIT | -3.58M | 644.70K | -1.96M | -1.84M | -3.16M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.90 | 1.00 | -3.35 | -8.21 | -16.95 |
| Normalized Basic EPS | -1.81 | 0.63 | -2.09 | -5.13 | -10.59 |
| EPS Diluted | -2.90 | 1.00 | -3.35 | -8.21 | -16.95 |
| Normalized Diluted EPS | -1.81 | 0.63 | -2.09 | -5.13 | -10.59 |
| Average Basic Shares Outstanding | 1.23M | 659.40K | 587.80K | 379.60K | 206.70K |
| Average Diluted Shares Outstanding | 1.23M | 659.40K | 587.80K | 379.60K | 206.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |